nonalcoholic fatty liver disease. Other diseases of liver
Conditions
Interventions
Intervention 1: Intervention group: They will receive powder of aqueous extracts of 15 g chicory (equivalent to 1 g of extract) prepared by Avigeh Tejarat Sepehr Co. as two 500 mg capsules daily, for
Treatment - Drugs
Placebo
Intervention group: They will receive powder of aqueous extracts of 15 g chicory (equivalent to 1 g of extract) prepared by Avigeh Tejarat Sepehr Co. as two 500 mg capsules daily, for 12 weeks.
Control group: The control group will receive daily 1 g of starch as placebo in the form of two 500 mg capsules similar to Chicory capsules for 12 weeks.
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: diagnosis of NAFLD according to ultra-sonography age between 18 to 65 years increase SGPT leve more than 30mgr/dl
Exclusion criteria
Exclusion criteria: Other causes of liver disease, including viral hepatitis or autoimmune, high alcohol consumption (more than 210 g / week in men and more than 140 g / week in women), Wilson's disease, hereditary hemochematosus, alpha1-antitrypsin deficiency and cirrhosis gestation and lactation; diagnosis of cancers consumption of hepatotoxic drugs or drugs using for management of NAFLD diagnosis of cardiovascular diseases diagnosis of diabetes mellitus diagnosis of hypothyroidism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Grade of fatty liver. Timepoint: before & 12 weeks after intervention. Method of measurement: liver and bile duct supersonic graphy.;Aspartate aminotransferases. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Waist circumfrence. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: by using of meter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum Alanine Aminotransferase. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum ALP. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Weight. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: Mechanical scale.;Serum triglyceride. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Total cholestrol. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum HDL. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Serum LDL-C. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample.;Fasting plasma glucose. Timepoint: before intervention, 6 weeks after beginning of the intervention, 12 weeks after beginning of the intervention. Method of measurement: blood sample. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa Asar
Qazvin University of Medical Sciences
Outcome results
None listed